Lymphoid malignancies: A decade and a half of dramatic improvements in outcome

Clinical Lymphoma and Myeloma

Volumn 8, Issue SUPPL. 4, 2008, Pages

  Zelenetz, Andrew D ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ABT 263; ALEMTUZUMAB; ANTINEOPLASTIC AGENT; BENDAMUSTINE; BORTEZOMIB; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLAVOPIRIDOL; FLUDARABINE; HEAT SHOCK PROTEIN 90 INHIBITOR; IBRITUMOMAB TIUXETAN; IMMUNOMODULATING AGENT; LENALIDOMIDE; MELPHALAN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD20; MONOCLONAL ANTIBODY CD40; MONOCLONAL ANTIBODY CD80; OBATOCLAX; OBLIMERSEN; PREDNISONE; PROTEIN BCL 2 INHIBITOR; RITUXIMAB; THALIDOMIDE; TOSITUMOMAB I 131; VINCRISTINE;

AUTOLOGOUS STEM CELL TRANSPLANTATION; B CELL LYMPHOMA; CANCER REGRESSION; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; DRUG APPROVAL; DRUG EFFICACY; EDITORIAL; EVIDENCE BASED MEDICINE; HUMAN; LYMPHOMA; MULTIPLE MYELOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL;

EID: 51049107883     PISSN: 15579190     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLM.2008.s.007     Document Type: Editorial

References (11)

1. Horning SJ. Natural history of and therapy for the indolent non-Hodgkin's lymphomas. Semin Oncol 1993; 20(5 suppl 5):75-88.
2. Czuczman MS. CHOP plus rituximab chemoimmunotherapy of indolent B-cell lymphoma. Semin Oncol 1999; 26(5 suppl 14):88-96.
3. Fisher RI, LeBlanc M, Press OW, et al. New treatment options have changed the survival of patients with follicular lymphoma. J Clin Oncol 2005; 23:8447-52.
4. Zelenetz AD. Will radioimmunotherapy survive? Clin Adv Hematol Oncol 2007; 5:782-4.
5. Brenner H, Gondos A, Pulte D. Recent major improvement in long-term survival of younger patients with multiple myeloma. Blood 2008; 111:2521-6.
6. Kumar SK, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008; 111:2516-20.
7. Rai KR, Peterson BL, Appelbaum FR, et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med 2000; 343:1750-7.
8. Byrd JC, Rai K, Peterson BL, et al. Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. Blood 2005; 105:49-53.
9. Kearing MJ, O'Brien S, Albitar M, et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 2005; 23:4079-88.
10. Chanan-Khan AA, Cheson BD. Lenalidomide for the treatment of B-cell malignancies. J Clin Oncol 2008; 26:1544-52.
11. Byrd JC, Lin TS, Dalton JT, et al. Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia. Blood 2007; 109:399-404.